Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 21/01/2026 am IST			5-day change	1st Jan Change
733.78 ^USD	+0.10%		-3.31%	-4.93%

20/01	RBC Cuts Price Target on Regeneron Pharmaceuticals to $745 From $766, Keeps Sector Perform Rating	MT
16/01	Where the Money's Moving

Analyst Reco.

20/01	RBC Cuts Price Target on Regeneron Pharmaceuticals to $745 From $766, Keeps Sector Perform Rating	MT
13/01	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating	MT
13/01	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating	MT
09/01	Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $911 From $818, Maintains Outperform Rating	MT
08/01	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $914 From $807, Maintains Buy Rating	MT
08/01	RBC Raises Price Target on Regeneron Pharmaceuticals to $766 From $708, Keeps Sector Perform Rating	MT
07/01	BofA Securities Upgrades Regeneron Pharmaceuticals to Buy From Underperform, Raises Price Target to $860 From $627	MT
07/01	Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says	MT
19/12	Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating	MT
17/12	Leerink Partners Adjusts Regeneron Pharmaceuticals PT to $873 From $710, Maintains Outperform Rating	MT
12/12	Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating	MT
10/12	Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating	MT
04/12	BMO Capital Adjusts PT on Regeneron Pharmaceuticals to $850 From $725, Maintains Outperform Rating	MT
04/12	Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating	MT
04/12	Analyst recommendations: Gitlab, Meta, PayPal, Salesforce, Dollar Tree…
04/12	Regeneron Shares Fall After Morgan Stanley Downgrade	MT
03/12	Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says	MT
03/12	Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equalweight From Overweight, PT is $767	MT
03/12	Analyst recommendations: Applovin, Garmin, Lyft, Uber, Netflix…
24/11	HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target	MT
20/11	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $800 From $723, Keeps Outperform Rating	MT
20/11	Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $700 From $615, Maintains Equalweight Rating	MT
13/11	Scotiabank Initiates Regeneron Pharmaceuticals at Sector Perform With $650 Price Target	MT
07/11	UBS Adjusts Price Target on Regeneron Pharmaceuticals to $660 From $595, Maintains Neutral Rating	MT
07/11	Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs

January 14, 2026 at 02:38 am IST